MedTrace Logo

Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

NCT03846180 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1682

Last updated 2019-07-05

No results posted yet for this study

Summary

Terlipressin and somatostatin/octreotide are the first-line choices for the treatment of acute variceal bleeding in liver cirrhosis. Acute kidney injury can develop in patients presenting with acute variceal bleeding. On the other hand, evidence suggests that terlipressin can reverse hepatorenal syndrome. It has been hypothesized that terlipressin can protect the renal function in cirrhotic patients with acute variceal bleeding, except for control of bleeding.

Conditions

  • Variceal Hemorrhage
  • Cirrhosis, Liver
  • Kidney Injury

Interventions

DRUG

Terlipressin

Continuous or intermittent intravenous infusion of terlipressin was given.

DRUG

Somatostatin

Continuous or intermittent intravenous infusion of somatostatin was given.

DRUG

Octreotide

Continuous or intermittent intravenous infusion of octreotide was given.

Sponsors & Collaborators

  • General Hospital of Shenyang Military Region

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2019-06-30
Completion
2019-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846180 on ClinicalTrials.gov